![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 15, 2020
For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
April 15, 2020
A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib
April 15, 2020
April 15, 2020
April 15, 2020
A Standing Main Member of ECOG-ACRIN since 2002
April 15, 2020
A one-of-a-kind cancer care delivery research trial that offers young women with cancer an assessment of their goals for fertility and family planning to make the most of cancer treatment and preserve future reproductive health
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
February 28, 2020
Mike Thompson writes that educating and engaging the public--both via social media and in person--is necessary to sustain a national clinical trials infrastructure and continue advancing cancer research
February 28, 2020
February 28, 2020
This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin
January 14, 2020
Reflecting on key milestones in 2019: TMIST breast cancer screening trial continues to ramp up; NCORP grant renewal emphasizes screening, symptom control, and cancer care delivery research; new role for Dr. Al Benson; E1912's practice-changing trial results; update on Dr. Otis Brawley's efforts to form the Social Determinants of Health Working Group; EA launches the Comis Symposium
January 13, 2020
Lower chemoradiation doses may effectively treat early stage anal cancer while improving quality of life